CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Sr. Vice President-Engineering bought 129,500 shares at an average $0.35 ($45,425)
- 4 Open-market buy Director bought 15,000 shares at $0.40 ($5,925)
- 4 Open-market buy Director bought 60,000 shares at an average $0.40 ($24,049)
- 4 Open-market buy Director bought 60,000 shares at an average $0.33 ($19,607)
- 4 Open-market buy President and CEO bought 72,805 shares at an average $0.33 ($23,914)
- 4 Open-market buy Director bought 120,800 shares at an average $0.30 ($36,573)
- 4 Open-market buy Director bought 60,000 shares at an average $0.28 ($16,848)
- 4 Open-market buy President and CEO bought 8,500 shares at an average $0.30 ($2,524)
- 4 Open-market buy Director bought 100,000 shares at an average $0.27 ($27,481)
- 4 Open-market buy Director bought 120,000 shares at an average $0.28 ($33,620)
- 4 Open-market buy Director bought 135,000 shares at an average $0.29 ($38,794)
- 4 Open-market buy Director bought 200,000 shares at an average $0.28 ($55,844)
- 4 Open-market buy President and CEO bought 45,000 shares at an average $0.22 ($10,120)
- 4 Open-market buy Director bought 100,000 shares at an average $0.23 ($23,120)
- 4 Open-market buy Director bought 50,000 shares at $0.25 ($12,500)
- 4 Open-market buy President and CEO bought 25,000 shares at $0.21 ($5,243)
- 4 Open-market buy Director bought 100,000 shares at an average $0.21 ($20,970)
- 4 Open-market buy Director bought 100,000 shares at an average $0.21 ($20,525)
- 4 Other acquisition Director acquired 10,471 shares (other)
- 4 Other acquisition Director acquired 10,471 shares (other)
Page 18 of 24 · 471 filings